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Abstract 20 
During human adenovirus 5 infection, a temporal cascade of gene expression leads ultimately to 21 
the production of large amounts of the proteins needed to construct progeny virions. However the 22 
mechanism for activation of the major late gene that encodes these viral structural proteins has 23 
not been well understood. We show here that two key positive regulators of the major late gene, 24 
L4-22K and L4-33K, previously thought to be expressed under the control of the major late 25 
promoter itself, are initially expressed from a novel promoter that is embedded within the major 26 
late gene and dedicated to their expression. This L4 promoter is required for late gene expression 27 
and is activated by a combination of viral protein activators produced during the infection, 28 
including E1A, E4 Orf3 and the intermediate phase protein IVa2, and also by viral genome 29 
replication. This new understanding re-draws the long-established view of how adenoviral gene 30 
expression patterns are controlled and offers new ways to manipulate that gene expression 31 
cascade for adenovirus vector applications.32 
3 
Introduction 33 
Although years of study have produced a detailed understanding of most molecular events during 34 
human adenovirus type 5 (Ad5) infection (4, 27), how the transition in viral gene expression from 35 
the early to the late phase is controlled has remained poorly defined. This control is crucial since 36 
it determines the activity of the genes that encode virion proteins, and hence the productivity of 37 
the infection. Residual activity from these genes is a confounding factor in the utility of E1-38 
deleted Ad5 vectors for long-term gene delivery (51). 39 
Initial expression of E1A from the linear Ad5 genome provides transcriptional activators that, 40 
with host proteins, turn on expression of the remaining early genes E1B, E2, E3, E4 (Fig. 1A). 41 
The major-late transcription unit (MLTU) is also weakly active at this time, but only the most 5’ 42 
proximal L1 product is produced (1, 35, 41). Around the time of transition to the late phase of 43 
infection, when replication of the viral genome also begins, transcription of intermediate genes 44 
IX and IVa2 commences (13, 39, 48, 49), while major-late promoter (MLP) activity greatly 45 
increases and its scope expands to direct expression of a full set of around 15 MLTU products 46 
from regions L1-L5 via alternative splicing and polyadenylation (35, 41). This transition in 47 
MLTU activity reflects transcriptional and post-transcriptional changes, both of which require 48 
proteins encoded in the MLTU L4 region (Fig. 1B). L4-22K and L4-33K act post-49 
transcriptionally to activate the production of the full set of MLTU mRNAs (16, 33, 44). At the 50 
same time, the MLP is further activated by IVa2 protein (30, 45) working with L4-22K and/or 51 
L4-33K (2, 33, 38). 52 
The essential role of L4-22K and L4-33K in producing full late-phase expression from the Ad5 53 
MLTU creates a paradox since, according to the current model of Ad5 gene expression, their 54 
expression is only achieved as a consequence of this activation process. Here we show that a 55 
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novel Ad5 promoter expresses L4-22K and L4-33K independently from the MLP, resolving this 56 
paradox, and that this promoter is activated by a combination of viral proteins and viral DNA 57 
replication. 58 
Materials and Methods 59 
Plasmids. pTG3602-Ad5wt (pWT) is a clone of the complete wild type Ad5 genome (11); 60 
pTG3602-L4-22K- (pL4-22K-)  was derived from pWT and contains a premature stop codon 61 
within the C-terminal unique portion of the L4-22K ORF (38). Linear genome was prepared from 62 
each of these plasmids by PacI digestion. Specific protein expression plasmids pCMV-IX (9),  63 
pMEPCMV-IVa2 (7), pCMV22KFLAG, pCMV33KFLAG and pCMV100KFLAG (33), 64 
pcDNA3.1Orf3 and pcDNA3.1Orf3 N82A (21) have been described previously. pE1A, provided 65 
by J. Logan, contains Ad5 1-5788 cloned between the EcoRI and SalI sites of the pBR322 66 
derivative, pML2, and with a deletion of the Ad5 SacI fragment 1770-5644.  pcDNA3.1Orf6 67 
contains the Ad5 E4Orf6 sequence (34089-33182), obtained by PCR and cloned at the EcoRI site 68 
of pcDNA3.1. 69 
L4 luciferase reporter plasmids were generated by amplifying various fragments in the region of 70 
Ad5 25887-26295 using primer pairs containing restriction recognition sites for KpnI (5’ primer) 71 
and NheI (3’ primer) and cloning using these sites into pGL3-Basic luciferase reporter plasmid 72 
(Promega). pcDNA3.1HisLacZ (Invitrogen) was used as a transfection control. pA-22/33KFLAG 73 
was generated by amplifying the relevant sequence as an EcoRI fragment from Ad5 strain 300 74 
wild-type viral DNA. pA-22KFLAG was generated from pA-22/33KFLAG by exchanging the 75 
HindIII/EcoRI 3’ fragment (Ad5 26328 to 26785 and C-Terminal FLAG tag) with the equivalent 76 
fragment from pCMV22KFLAG (33).  77 
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pLoxPGFP was obtained by modification of pBiEGFPPacI (16), with insertion of a LoxP 78 
sequence between the promoter PBi-1 and the EGFP ORF and a zeocin resistance gene driven by 79 
the thymidine kinase promoter. L4 shuttle plasmids were constructed from pBiEGFPPacI (16) by 80 
first replacing the PBi-1 promoter and EGFP with a LoxP sequence and adding a hygromycin 81 
resistance cassette from pTK-Hyg (Clontech), and then inserting one of several L4 cassettes 82 
downstream of LoxP. These were: (a) TPL-L4 cassettes, comprising the Ad5 tripartite leader 83 
(6049-6089, 7111-7182, 9644-9733) and 109bp intron sequence downstream of leader 3 (9734-84 
9842), joined to L4 sequence from either 198bp upstream of 100K ORF or 177bp upstream of 85 
22/33K ORF to a C-terminal FLAG tag on L4-33K giving pShuttle100/22/33KFLAG and 86 
pShuttle22/33KFLAG respectively; (b) L4-only cassettes comprising the L4 components of the 87 
TPL-L4 cassettes, giving pShuttle26018-22KFLAG and pShuttle26018-22/33KFLAG; or (c) the 88 
L4-22/33K ORF alone from its AUG at 26195, giving pShuttle22/33KFLAG ORF. 89 
Production of L4P- genome. pBR322∆HindIII was generated by digesting pBR322 with HindIII, 90 
end-filling with DNA polI (Klenow fragment) and re-ligating. The NdeI fragment from pWT was 91 
subcloned into pBR322∆HindIII to generate pWTNdeI19548-31088. The core promoter (26018-92 
26098) was deleted from this subclone by a two-step PCR protocol using primers that 93 
incorporated sequence from each side of the deletion (Ad26003-26017/26099-26119f and 94 
Ad26112-26099/26017-25997r) with 3’ and 5’ flanking primers (Ad26511-26487r and Ad25198-95 
26027f respectively). The second stage PCR product (25198-26511) with the core promoter 96 
deleted was digested with AscI and HindIII at sites within the Ad5 sequence and used to replace 97 
the equivalent wild-type sequence, generating pWTNdeI19548-31088∆P. The NdeI fragment 98 
from pWTNdeI19548-31088∆P was then recloned into pWT to generate pL4P-, from which 99 
linear genome was prepared as above. 100 
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Cell Culture. 293 and HeLa cells were maintained in Dulbecco’s MEM (DMEM) supplemented 101 
with 10% newborn bovine serum. 293TETOFF cells (Clontech) and their derivatives were 102 
maintained in DMEM plus 10% fetal bovine serum on plates precoated with polylysine. Full 103 
details of the isolation of L4 cell lines will be presented elsewhere. Briefly, 293TETOFF cells, 104 
preselected for stable expression of GFP following pLoxPGFP transfection and Zeocin selection, 105 
were transfected with either pShuttle100/22/33KFLAG or pShuttle22/33KFLAG together with 106 
500ng Cre recombinase expression plasmid (pCre; Invitrogen) and hygromycin-resistant lines 107 
isolated. 108 
Transfection and Inhibitors. Transient transfections were carried out in 12 well cultures with 109 
cells plated at a density of 7x105 cells/well, using TransIT-LT1 (Cambridge Bioscience) at a ratio 110 
of 3µl / µg DNA following the manufacturers’ protocols. For inhibition of ATM/ATR signalling, 111 
cells were pre-treated with 3mM caffeine for 3h, washed twice with serum-free medium and then 112 
transfected as above. 5h post-transfection, medium was replaced with medium containing 3mM 113 
caffeine until harvest 48h post-transfection. For inhibition of viral DNA replication in genome-114 
transfected cells, 5h post-transfection media were replaced with media containing 10mM 115 
hydroxyurea until harvested 48h post-transfection.  116 
Luciferase Reporter Assays. Assays were performed as previously described (33). β-117 
galactosidase activity was used to correct luciferase levels for differences in transfection 118 
efficiency. The effect of added E1A on β-galactosidase expression in HeLa cells was adjusted for 119 
using the ratio of mean activity between cells expressing and not expressing E1A. Data are 120 
shown either as fold-induction, where mean corrected luciferase expression from the specified 121 
basic or parental reporter plasmid is set as 1, or as % activity of the defined L4 promoter reporter 122 
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(25887-26125). Values shown are the mean of triplicate independent determinations within an 123 
experiment, and are representative of multiple independent experiments.  124 
Antibodies. Proteins were detected using the following antibodies: anti-FLAG rabbit polyclonal 125 
serum (Sigma) at 1:10,000 for western blotting and at 1:1000 for immunofluorescence; AbJLB1 126 
rabbit polyclonal serum to Ad5 late proteins at 1:10,000 (16); rabbit anti-L4-100K (W. C. Russell, 127 
University of St Andrews) at 1:10,000 for western blotting and 1:1000 for immunofluorescence; 128 
rabbit anti-L4-33K at 1:1000 (18); mouse anti-DNA binding protein MAb B6-8 at 1:10,000 (40); 129 
anti-E4-Orf3 (6A11) rat monoclonal antibody at 1:500 (34); rabbit anti-IVa2 at 1:10,000 (7); and 130 
anti-β-tubulin mouse mAb (Sigma) at 1:200. Secondary antibodies were goat-anti-mouse IgG-131 
horseradish peroxidise (HRP) conjugate (Sigma) at 1:5000, goat-anti-rabbit IgG-HRP (Santa 132 
Cruz) at 1:100,000, goat-anti-rat IgG-HRP (Chemicon) at 1:100,000 and Alexafluor594 goat-133 
anti-rabbit IgG (Invitrogen) at 1:500.  134 
Protein Expression Detection. Transfections used 500ng pA-22KFLAG or pA-22/33KFLAG 135 
alone or co-transfected with either 1µg linear viral genome or 500ng various expression plasmids. 136 
All transfections were equalised for DNA content by the addition of either salmon sperm DNA or 137 
empty vector to account for the absence of genome or expression plasmid respectively. 138 
Transfected cells were harvested 48h post-transfection and FLAG-tagged proteins isolated using 139 
anti-FLAG (M2) agarose as described previously (21). Samples corresponding to 50% volume of 140 
immunoprecipitated proteins and 1-2% volume of cell lysates taken prior to immunoprecipitation 141 
were resolved through either 10% or 15% SDS-polyacrylamide gels as appropriate. Proteins were 142 
transferred to ECL nitrocellulose membrane (GE Healthcare) and western blot analysis carried 143 
out as described (29) using horseradish peroxidise-conjugated secondary antibodies and detection 144 
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via ECL-Advance (GE Healthcare). Immunofluorescence was performed as previously described 145 
(28). 146 
Results 147 
Expression of Ad5 L4 22/33K and 100K proteins is separately regulated 148 
Early data showing that L4 mRNAs accumulated before those from L2, L3 and L5 during the 149 
onset of the late phase suggested that L4 expression might be regulated differently from other 150 
MLTU regions although transcription rate data did not suggest any additional promoter within 151 
the MLTU (25). L4 encodes several proteins (Fig. 1B). During attempts to produce stable cell 152 
lines expressing L4-100K, 22K and 33K proteins from a shortened MLTU under control of a 153 
tetracycline-regulated promoter (Fig. 2A), cells were repeatedly obtained that showed correctly 154 
inducible 100K expression but constitutive expression of 33K (Fig. 2B). Similar constructs 155 
designed to express just the 22K and 33K proteins also gave only constitutively expressing cell 156 
lines (Fig. 2C) while the shuttle plasmids (Fig. 2D) used to produce these cell lines produced 157 
readily detectable 33K in transient assays despite lacking any known promoter (Fig. 2E, F). 158 
Removal from these constructs of all Ad5 sequence upstream of the L4-33K reading frame 159 
abolished this expression (Fig. 2E). These results suggested that L4 22/33K could be expressed 160 
from a novel viral promoter, independent of the Ad5 MLP.  161 
Ad5 L4 contains a promoter for 22K/33K expression  162 
The promoterless shuttle plasmids, which nonetheless expressed L4-33K, retained the Ad5 DNA 163 
that encodes the tripartite leader (TPL) which is spliced onto all MLP-encoded mRNAs during 164 
Ad infection. However, this was not required for L4-22/33K expression as plasmids lacking this 165 
TPL-encoding sequence were equally capable of expressing these proteins (data not shown). 166 
Attention therefore focused on the 177 bp of L4 DNA upstream of the 22/33K start codon also 167 
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present in these constructs, which was hypothesised to contain a promoter for L4 22/33K 168 
expression. When this sequence plus 100 bp of the downstream 22/33K reading frame (Fig. 3A, 169 
construct B) was placed in front of a promoterless luciferase reporter gene, it caused a modest 4-170 
fold increase in activity (Fig. 3B). However, extending the sequence further upstream to position 171 
25887 increased activation to 40-fold (Fig. 3B, construct E). Similar analysis of a series of 172 
constructs with different lengths of Ad sequence showed an essential sequence for the L4 173 
promoter was located between 26018 – 26098 bp. This sequence alone activated luciferase 174 
expression more than 10-fold (Fig. 3B, construct D) and its deletion from the full promoter 175 
completely destroyed activity (Fig. 3C, construct I). Including sequence upstream of this essential 176 
sequence to position 25887 greatly increased promoter activity, while sequences downstream to 177 
26125 were repressive; however, the presence of the upstream sequences overcame this 178 
repressive effect (Fig. 3B). The full L4 promoter (L4P), which gave >80-fold increase in activity 179 
over background, was therefore designated as Ad5 position 25887 – 26125. The addition of 180 
further downstream sequence, to position 26296, gave lower activity than the full promoter, 181 
possibly because this sequence includes the L4 22/33K AUG, which would reduce translation 182 
from the luciferase start codon. Alternatively, this decrease in activity may be due to negative 183 
control elements within the extended region. 184 
Previously described Ad5 promoters are activated by the E1A proteins that are produced in the 185 
earliest stages of infection. These E1A proteins are constitutively expressed in 293 cells, where 186 
L4P activity was first detected (Fig. 3B). The importance of E1A to L4P activity was therefore 187 
tested in HeLa cells, in which basal activity of the promoter was very low. Activity was increased 188 
40-fold by E1A, whereas adding further E1A in 293 cells gave only a 6-fold enhancement of a 189 
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much higher basal level (Fig. 3D). Thus the L4P is responsive to E1A. Co-transfection of wt Ad5 190 
genome also strongly activated the promoter (Fig. 3D); this activation is explored further below. 191 
L4 promoter is functionally relevant and required for infection to enter late phase 192 
To determine whether L4P in its natural context directed expression of L4 proteins, DNA from 193 
position 25887 to the 3’ end of the 22K coding sequence (FLAG tagged for detection and with a 194 
polyA site added) was cloned into a plasmid with no other viral or eukaryotic sequences present 195 
(pA-22KFLAG). This plasmid alone expressed little or no 22K-FLAG in 293 cells, but when co-196 
transfected with 22K-deficient Ad5 genome 22K-FLAG was readily detected (Fig. 4A). Co-197 
transfected genome also activated expression of 33K from a similar construct capable of 198 
expressing both 22K (untagged) and 33K-FLAG (Fig. 4B). Ad5 superinfection also activated 199 
L4P in HeLa cells (data not shown). To test whether these amounts of 22K expressed from L4P 200 
were functionally significant, we made use of a complementation assay using Ad5 22K- genome. 201 
Such genomes are substantially defective in the synthesis of all proteins encoded in the MLTU 202 
but can be complemented in trans with a 22K expression plasmid (33). Using this test, L4P 203 
directed expression of functional amounts of 22K-FLAG, either from a 22K-only construct (Fig. 204 
4C) or from a 22/33K construct (Fig. 4D). L4P is therefore active in its natural context and the 205 
amount of 22K it produces is sufficient to promote the early – late transition in MLTU activity. 206 
To show the importance of L4P to the life-cycle of the virus, the sequence 26018-26098 207 
(essential for L4P activity; Fig. 3C) was deleted within full length wild-type genome plasmid to 208 
create L4P- genome. This deletion also disrupts the essential L4-100K open reading frame, 209 
however late proteins (except hexon) are still expressed from MLTU plasmids in the absence of 210 
100K (16) meaning that the importance of L4P for gene expression from the MLTU could be 211 
tested using this mutant genome.  The L4P- genome expressed amounts of DBP, a representative 212 
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early protein, equivalent to wild-type genome, but it essentially failed to express either MLTU-213 
derived proteins or IVa2, reproducing the phenotype of L4-22K- genome (Fig. 4E). 214 
Cotransfection of 22K expression plasmid with L4P- allowed significant expression of IVa2 and 215 
MLTU proteins, except hexon which accumulated when 100K was additionally expressed in 216 
trans. Thus, L4P- genome is functionally deficient in L4-22K. Although the promoter deletion is 217 
some distance upstream of the major splice acceptor site by which L4-22K and 33K are 218 
expressed from the MLP (position 26158), its use could have been affected by the deletion, so 219 
preventing 22K/33K expression. However this is not the case since L4-33K expression from L4P- 220 
genome was clearly induced following complementation with 22K in trans (Fig. 4E). Thus, the 221 
gross defect in late gene expression from L4P- genome is due to lack of L4 promoter activity, 222 
which is therefore required to initiate late phase gene expression. Surprisingly, co-transfection of 223 
L4P- with 100K alone did cause some increase in certain late proteins, particularly penton base, 224 
although substantially less than achieved by 22K complementation. This may reflect low levels 225 
of transcription from the MLP in the absence of L4-22K, from which translation can be enhanced 226 
by L4-100K. Alternatively, because, uniquely among the plasmids used here, the DNA present in 227 
the complementing L4-100K plasmid covers the L4P- deletion, some rescue of the mutation may 228 
be occurring by homologous recombination in this case only.  229 
Defining activators of the L4 promoter 230 
The strong activation of the L4 promoter by Ad5 genome in cells that already expressed E1A 231 
suggested that genome supplied activators in addition to E1A. Full late phase activation of the 232 
MLTU requires genome replication so, given the expected timing of activation of L4P at the 233 
early-late phase transition, we first tested whether or not replication of the added genome was 234 
required for its effect. Genome fragmented to prevent its replication by exhaustive digestion with 235 
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BglII+HindIII (digest 1: 23 fragments) still significantly activated L4P (Fig. 5A), suggesting that 236 
genome replication is not essential for L4P transactivation. However, replication must contribute 237 
to the activation caused by intact genome since: (a) digest 1 has somewhat lower activity than 238 
intact genome; and (b) hydroxyurea (HU), which blocks DNA synthesis among other effects, 239 
essentially blocked stimulation of the promoter by genome (Fig. 5B, D). 240 
 We considered the possibility that some component of L4P activation by complete or fragmented 241 
genome could be due to expression of specific viral proteins. Ad5 genome digest 2 (HaeII; 77 242 
fragments), which truncates or separates from their promoters all known open reading frames 243 
except protein IX, was a much less potent activator of the L4 promoter than genome digest 1, 244 
which could, in principle, express E1A, IX, IVa2 and E4 Orf1 from individual fragments (Fig. 245 
5A). Since additional E1A contributed only modestly to 22K expression from L4P in 293 cells 246 
(Fig. 5A), while E4 Orf1 is expressed late in Ad5 infection (14) and Orf1 mutants express late 247 
proteins normally (8, 43), the involvement of these proteins in genome-mediated L4P activation 248 
in 293 cells was unlikely. In contrast, production of IX and IVa2 begins around the early-late 249 
transition making them plausible L4P activators. When tested, IVa2 but not IX activated L4P 250 
significantly (Fig. 6A, B), although it was less potent than intact genome. 251 
Ad5 E4 Orf3 and E4 Orf6 were also tested for effects on L4 protein expression, initially because 252 
these proteins had been shown to affect MLTU splicing during Ad infection (36, 37) and it was 253 
conceivable that part of the induction of 22K by genome was by altering the splicing balance 254 
between 22K and 33K expression. However, both 22K (from pA-22KFLAG) and 33K (from pA-255 
22/33KFLAG) were induced by exogenous E4-Orf3 (Fig. 6C) suggesting this was not the case. 256 
Moreover, Orf3 activated L4P while Orf6 did not (Fig. 6A, E). Thus Orf3, like IVa2, is an 257 
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activator of L4P. Furthermore, this activity was retained by mutant Orf3 N82A (Fig. 6D), a 258 
protein which is defective in other Orf3 activities.  259 
The fact that highly fragmented genome (digest 2: 77 fragments) was still able to activate L4P to 260 
some extent (Fig. 5A), even though it was incapable of replicating or expressing any viral 261 
proteins other than potentially IX, which did not activate in trans, suggested that a general stress / 262 
DNA damage response, consequent upon the transfection of this fragmented DNA, might be 263 
affecting the promoter. During infection, replicating linear adenovirus genome also activates this 264 
response. In support of this idea, a non-specific fragmented DNA also activated L4P (Fig. 5C). 265 
Fragmentation of the DNA was clearly the critical factor in this activating response since the 266 
same DNA was used unfragmented as the transfection control in all these experiments and had no 267 
effect on the promoter. Cellular responses to double-strand DNA breaks are signalled via the 268 
kinase ATM, which is inhibited by caffeine. However, caffeine treatment did not inhibit L4P 269 
activation by digested genome (Fig. 5D). Thus the mechanism by which L4P is activated by 270 
fragmented DNA remains unclear. 271 
Discussion 272 
Our data show that L4-22K and 33K expression is driven by a previously undetected 273 
intermediate-phase promoter (L4P) embedded within the body of the Ad5 MLTU, and that this 274 
promoter triggers progression of infection into the late phase. The ability of Ad5 to produce L4-275 
22/33K proteins independent of the MLP resolves the paradox created by these otherwise MLP-276 
derived proteins being required for their own production. This discovery therefore fills a 277 
significant gap in our understanding of how the Ad5 infectious cycle progresses to virus 278 
production. 279 
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As might have been expected from knowledge of other Ad5 promoters, L4P activity was strongly 280 
upregulated by several virus-derived factors. In particular, L4P was strongly activated by the 281 
presence and replication of viral genome. This stimulation was partly attributable to expression of 282 
viral protein activators, including E1A, E4 Orf3 and IVa2, synthesis of the latter itself being 283 
dependent on the onset of DNA replication (22). The role of E1A proteins was not surprising 284 
since they activate several other Ad promoters (5, 23). Similarly, the role of IVa2 in L4P 285 
activation fits with its induction at the onset of replication and with its role as a transcription 286 
factor in activating the MLP (32, 45). Since we have recently shown that L4-22K increases the 287 
levels of IVa2, probably through protein:protein interaction and stabilization (33), there is thus a 288 
mutual enhancement relationship between these two proteins. This creates a molecular switch 289 
that can re-enforce itself to drive the infection into the late phase.  290 
The involvement of IVa2 in L4P activation may explain, at least in part, the increased activation 291 
of L4P that is observed when co-transfected genome is able to replicate, since expression of IVa2 292 
is itself activated by replication (22). IVa2 expression may also account for some of the 293 
difference in L4P transactivation activity between digested genome preparations 1 and 2. Where 294 
the IVa2 gene remained intact (digest 1), the genome fragment preparation was still able to 295 
express low levels of IVa2 (data not shown) whereas equivalent amounts of digest 2 were, 296 
unsurprisingly, unable to express any IVa2 protein. However, there remains a component of 297 
activation by highly fragmented genome that cannot be accounted for by protein expression and 298 
which is not specific to the presence of Ad5 sequences. The basis of this component of L4P 299 
transactivation remains to be determined. 300 
The relevance to L4P activation of known Orf3 activities, which either disrupt DNA damage 301 
responses through mislocalization of key cellular proteins (42), disrupt promyelocytic leukaemia 302 
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(PML) nuclear bodies through direct interaction with PML protein (10, 15, 21) to overcome 303 
antiviral responses (46, 47), or bind the transcription factor TIF1α (52), can be discounted since 304 
these activities are lost by the Orf3 N82A mutant, which we have shown retains full activity 305 
towards L4P. Two further Orf3 activities, regulation of MLTU RNA splicing (36, 37) and relief 306 
of the repression of cellular p53 activity that is imposed by other viral proteins during the early 307 
phase of infection (24), have not been tested for the N82A mutant, however Orf3 activation of 308 
L4P was not diminished by a significant reduction in p53 levels (data not shown), suggesting that 309 
Orf3 does not act via this route. Thus the basis for the activation of L4P by E4 Orf3 remains to be 310 
determined. 311 
Differences were observed between the activity of L4P when incorporated into 293-based cell 312 
lines within an inducible expression cassette and when used transiently to drive L4-22K/33K 313 
expression. In the former case, expression of L4 proteins (via their FLAG tag) was detectable 314 
without additional inducers, whereas the plasmid-based promoter required induction by one or 315 
more of several factors in order for its protein product to be detected. There are two potential 316 
reasons for this difference. First, the level of protein detected in cell lines reflects accumulation to 317 
steady state over a considerable time whereas in a transient assay the level of protein observed is 318 
more dependent on its rate of synthesis. Second, the basal activity of L4P appears to be sensitive 319 
to the state of the cells since, in some transient assays, a low level of 22K was detected from L4P 320 
in the absence of genome and we have shown L4P induction by fragmented DNA, a known cell 321 
stressor. Because the cell lines were maintained in a cocktail of drugs to maintain the appropriate 322 
selection regime, this may also have imposed a stress on the cells that served to activate L4P. 323 
There were also differences in the requirement for specific activators to observe detectable L4P 324 
activity between the natural context where L4P was driving expression of L4-22K and the 325 
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luciferase reporter context. In the natural context, activity was highly dependent on activators 326 
provided by viral genome while considerable luciferase reporter activity was seen in the absence 327 
of activation, although this was further increased by trans-activation. We believe this difference is 328 
likely to be due to the presence of negative regulatory elements downstream of our mapped 329 
promoter region, within the 22/33K coding sequence. 330 
The DNA sequence within the mapped L4P contains potential binding sites for a large number of 331 
transcription factors, including known mediators of E1A activation such as E2F and ATF that 332 
may well be significant in the activity of L4P as well as numerous other factors, the significance 333 
of which cannot be predicted. It is notable that there is no obvious TATA box in the promoter 334 
region and in this respect L4P is similar to the IVa2 promoter, which depends for its activity on 335 
an initiator element at the transcription start site (12). However, the functional significance of this 336 
lack of TATA box is uncertain since TATA boxes, although once thought to be fairly ubiquitous 337 
features of eukaryotic promoters, have been more recently shown to be present in only around 338 
25% of genes in genome-wide surveys (50).  339 
L4P overlaps with the E2 late promoter (E2-L) on the opposite genome strand. Like L4P, E2-L 340 
becomes active during the intermediate phase of infection (3). However, the two promoters have 341 
different sequence requirements, with sequence from 25910-26065 providing E2-L full activity 342 
with correct temporal regulation within the Ad replication cycle (6) while the minimum  L4 343 
promoter was shown here to be 26018-26098. Moreover, the two promoters differ in their 344 
response to E1A, L4P being activated by E1A while E2-L is insensitive (26) or repressed (20). 345 
Thus, L4P and E2-L are distinct and independent in their regulation. 346 
The discovery of L4P creates a new understanding how the full late phase of Ad5 infection is 347 
initiated which is important in two ways. First, it creates a new opportunity to enhance the 348 
17 
properties of Ad5-based gene delivery vectors. E1-deleted vectors have been intensively 349 
investigated for many applications, but in situations where long-term persistence of the delivered 350 
gene is required, cellular immune responses to residual viral gene expression products are a 351 
significant confounding factor (51). Whilst these problems can be avoided by removing all viral 352 
genes from the vector (31), such vectors are difficult to produce in quantity. Second, the 353 
importance of L4P can be speculatively linked to the ability of Ad5 to persist for extended 354 
periods in lymphoid cells in its natural host (17, 19). This property requires that Ad5 can regulate 355 
its infectious cycle to limit or prevent commitment to the late phase. The discovery of the 356 
essential role of L4P therefore presents further avenues through which to explore this aspect of 357 
Ad5 biology. 358 
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Figures  508 
 509 
Figure 1. (A) The Ad5 transcription map showing immediate early (light grey), early (black), 510 
intermediate (white) and major late transcription units (MLTU; dark grey arrows), which are 511 
expressed during infection in a temporal cascade (bottom). All transcription units except IX and 512 
IVa2 produce multiple mRNAs and protein products by alternative RNA processing. MLTU 513 
mRNAs each comprise the three exons of the tripartite leader (TPL) spliced to one of ~15 514 
possible acceptor sites within regions L1-L5. (B) Organisation of the L4 region of the MLTU 515 
showing L4-100K, L4-22K, L4-33K and pVIII ORFs, with 3’ splice sites for their expression 516 
from the major late promoter. L4-22K and 33K share the same N-terminal sequence but have 517 
distinct C-termini. 518 
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 519 
Figure 2. Differences in control of L4-22K, L4-33K and L4-100K expression. (A) Schematic 520 
representing the method for generating stable L4-protein cell lines. Target cells express GFP 521 
under doxycyclin control and this gene is then replaced with L4 sequences by Cre-mediated 522 
recombination with a promoterless shuttle plasmid. (B) 100/22/33KFLAG cells containing the L4 523 
region linked to a tetracycline-regulated promoter or parental 293TETOFF cells were grown in 524 
the presence (+) or absence (-) of doxycycline for 3 days with daily media changes. L4-100K and 525 
L4-33KFLAG in total cell lysates were detected by western blot analysis. (C) 22/33KFLAG cells 526 
(a-d), or parental 293TETOFF cells (e-h) were grown in the presence (a, b, e, f) or absence (c, d, 527 
g, h) of doxycycline for 3 days with daily media changes. Cells were fixed and stained for 528 
26 
FLAG-tagged 33K (red) and for nuclear DNA (DAPI; blue) and images collected sequentially 529 
using a Leica SP2 confocal microscope, to avoid cross-talk between the fluors. FLAG and DAPI 530 
images were overlayed using Leica software (b, d, f, h); scale bar 20µm. (D) Schematic 531 
representation of the Ad5 sequences present in pShuttle plasmids. Brown: MLTU exon sequences 532 
(rightwards transcription); blue: E2A exon (leftwards transcription); pale brown: L4 ORFs as 533 
indicated. (E) Transient expression from promoterless L4 shuttle plasmids. 293TETOFF cells 534 
were transfected with pShuttle100/22/33KFLAG (a, b), pShuttle22/33KFLAG (c, d) or 535 
pShuttle22/33KFLAG ORF (e, f), or mock transfected (g, h). Cells were fixed and stained 48h 536 
later, and imaged as for panel C; scale bar 20µm. (F) 293TETOFF cells were mock-transfected or 537 
transfected with L4-22K- genome, together with either pShuttle100/22/33KFLAG or 538 
pShuttle22/33KFLAG. 33KFLAG protein in total cell lysates was detected by western blot 539 
analysis. Proteins molecular mass markers migrated to the positions shown on the left of panels B, 540 
F (kDa).  541 
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 542 
Figure 3. Defining sequences important for L4 promoter activity. (A) A schematic representation 543 
of the L4 sequences included in luciferase reporter constructs analysed in panels B-D. (B, C) 293 544 
cells were mock-transfected or transfected with luciferase reporter constructs containing as 545 
promoter varying lengths of L4 sequence (panel A).  Firefly luciferase activity, corrected for 546 
transfection efficiency using β-galactosidase expression from an independent control plasmid, is 547 
expressed (B) as fold difference from the activity of the promoterless reporter plasmid 548 
(pGL3Basic) or (C) as % of the activity of the full L4 promoter, construct F. (D) HeLa cells 549 
(black bars) or 293 cells (white bars) were transfected with construct D plus either empty vector, 550 
E1A expression plasmid or Ad5 wt genome (wt gen). Firefly luciferase activity, corrected as for 551 
(B, C), is expressed as fold difference from the activity of construct D in the presence of empty 552 
vector, which was set as 1. Each panel shows the mean values from biological triplicates within a 553 
single experiment (error bars, +/- standard deviation), and is representative of at least 3 554 
independent experiments. 555 
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 556 
Figure 4. L4-22K expression from L4 promoter is functionally significant. (A - D) 293 cells 557 
were mock-transfected or transfected with L4-22K- genome alone or plus either pA-22KFLAG 558 
(A, C) or pA-22/33KFLAG (B, D). Immunoprecipitated FLAG-tagged 22K (A) or 33K (B), or 559 
Ad5 late proteins in total cell lysates (C, D), were detected by western blot analysis. (E) Ad5 560 
wild-type (Wt), L4-22K- or L4P- genomes were transfected into 293 cells with combinations of 561 
expression plasmids for individual L4 proteins 100K, 22K and 33K as indicated. Total cell 562 
extracts were analysed as for (A, B) for specific viral proteins indicated to the right of the panel. 563 
29 
Where a blot with a given antibody is shown in segments, these were all taken from the same 564 
exposure of the same blot, with lanes rearranged for clarity of explanation. The positions to 565 
which proteins of known molecular mass migrated are indicated for all panels (kDa). 566 
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 567 
Figure 5. Activation of L4P by Ad5 genome. (A) 293 cells were mock transfected or transfected 568 
with pA-22KFLAG together with undigested Ad5wt genome (wt gen.), Ad5wt genome digested 569 
with either BglII/HindIII (digest 1) or HaeII (digest 2) or an E1A expression plasmid and 570 
22KFLAG detected as for Figure 4. (B) 293 cells were transfected with L4 promoter luciferase 571 
reporter construct D (Fig. 3A), with or without L4-22K- genome and/or treatment with 10mM 572 
hydroxyurea (HU) from 5h post-transfection.  Luciferase expression, corrected for transfection 573 
efficiency, is expressed as fold increase over the activity of core promoter alone, set as 1. Error 574 
bars show the standard deviation of three replicate determinations. The graph is representative of 575 
two experiments. (C) As panel A except using digested salmon sperm DNA as an L4P activator 576 
in comparison with intact Ad5 genome. (D) 293 cells were mock treated or pre-treated with 3mM 577 
caffeine for 3h, then mock-transfected or transfected with pA25887-22KFLAG together with 578 
intact Ad5wt genome or digest 1. From 5h post-transfection cells were maintained in DMEM or 579 
DMEM supplemented with 3mM caffeine (Caf) or 10mM hydroxyurea (HU). 580 
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 581 
Figure 6. Viral proteins activate the L4 promoter. (A, C, D) 293 cells were mock transfected or 582 
transfected with pA-22KFLAG or pA-22/33KFLAG, together with viral protein expression 583 
plasmids as indicated or Ad5wt genome. Immunoprecipitated 22KFLAG protein or proteins from 584 
unfractionated cell lysates were detected by western blot analysis as indicated at the right of each 585 
panel. The positions of molecular mass marker proteins are shown on the left (kDa). (B) 293 cells 586 
were mock transfected or transfected with L4 promoter luciferase reporter constructs D or F (Fig. 587 
3A), with or without IVa2 expression plasmid. Firefly luciferase activity, corrected for 588 
transfection efficiency, is expressed as fold difference from activity of the relevant promoter 589 
reporter alone, which was set as 1. Error bars show the standard deviation of three replicate 590 
determinations. (E) As panel B except cells were transfected with L4 promoter reporter construct 591 
D, with or without either E4-Orf3 or E4-Orf6 expression plasmids. The graphs are representative 592 
of two experiments. 593 
